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To the Editor: 
The incidence of esophageal adenocarcinoma (EAC) has been rapidly increasing in the Western 
societies in recent decades.
1
 Gastroesophageal reflux disease, obesity, and tobacco smoking are 
the major risk factors.
1,2
 EAC is characterized by a poor prognosis with an overall 5-year 
survival below 15-20%, which is even worse in patients diagnosed at late stages.
1
 Upper 
endoscopy is increasingly utilized for detection of the premalignant condition of EAC, i.e., 
Barrett’s esophagus with dysplasia. However, a universal screening strategy, even in patients 
with reflux, is infeasible given the considerable costs and risk of complications, and the low 
incidence (0.7 per 100 000 person-years globally, and the highest 7 per 100 000 years in men in 
the United Kingdom).
3,4
 Risk prediction models for EAC combining information on risk factors 
have recently been developed. These have had good discriminative accuracy and have shown 
promising potential in identifying high-risk individuals who might benefit from targeted 
prevention and early detection strategies.
5,6  
In this study, we further assessed the feasibility of targeted screening based on a risk prediction 
model using the Lorenz Curve. The Lorenz Curve is a graphical tool widely used in 
econometrics to characterizing the distribution of wealth in the society, which has been 
suggested to be valuable in demonstrating the “concentration” of disease risks.7 This tool may be 
particularly relevant when evaluating screening programs in the context of disease risk prediction.  
We have developed a risk prediction model based on data from a nationwide population-based 
case-control study in Sweden in 1995-1997.
2,5
 Participants included 189 histologically confirmed 
incident cases of EAC from all relevant hospital departments in Sweden, and 820 control 
subjects frequency- matched for age and sex and randomly selected from the Swedish population. 
Detailed information on risk factors was collected via face-to-face interviews. This study was 
approved by all six regional ethical review boards in Sweden, and both written and oral informed 
consent was obtained from each participant. In brief, we ranked the estimated risks for all 
controls (representing the population at risk) obtained from the logistic regression model. For 
each of the risk levels, the cumulative proportions of controls and estimated risks having this 
level of risk or below were used to draw the curve. Methodological details can be found in the 
report by Mauguen and Begg.
7
 
The constructed Lorenz Curve is shown in Figure 1. Based on a simple model, which only 
included information on reflux symptoms or use of antireflux medication, body mass index, and 
tobacco smoking, 37% of all EAC cases would occur in the 10% of the population with the 
highest risks, and 22% of all cases would be identifiable from the top 5% of the population based 
on risk. The estimated risks would be even more concentrated after also considering age and sex. 
For example, the risk concentration should be greater in men aged 50 years or older who 
contribute approximately 75% of all cases in the total population and thus represent a high-yield 
target for screening. 
These results highlight the significant concentration of EAC risks in the population and the 
usefulness of risk prediction models in identifying high-risk individuals for targeted early 
detection and prevention strategies. However, there remains certain overestimation of the risk 
concentration, given that we used the same dataset to assess the model with the Lorenz curve as 
it was developed from. Using an external independent dataset would be preferable. Furthermore, 
necessary cut-off points of estimated risk for clinical and public health use need to be carefully 
determined, in which related costs, potential benefits and risks for patients, and the absolute risk 
in the population should be taken into account. 
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 Figure 1. Lorenze curve for a model based on a case-control study on esophageal 
adenocarcinoma. 
